OCON Therapeutics
Pharmaceutical Manufacturing • 
Modiin-Maccabim-Reut, Center District, Israel • 21-50 Employees
Company overview
| Headquarters | 15 Hashdera Hamerkazit, POB 552, Modiin, Israel 7171801, IL |
| Phone number | +972722150105 |
| Website | |
| NAICS | 3254 |
| SIC | 384 |
| Keywords | Healthcare, Women'S Health, GP, Gynecology, Sexual Health, Family Planning, Obgyn, Women'S Lifestyle, Contraception, Hysterectomy, Drug Products, Birth Control, Intrauterine, IUD, AUB, Abnormal Uterine Bleeding, Ballerine, IUB, Larc, Non-Hormonal Contraception, The Sead, Baby Planning, Ball Contraception, Bio Investments, Hormone-Free Contraception, Innovative Contraception, Non Surgical Therapy |
| Founded | 2020 |
| Employees | 21-50 |
| Socials |
Key Contacts at OCON Therapeutics
Galit Levin
Director Of Research Development
Rachel Safra-Zafrany
Director Of Clinical Operations
Rafi Tzvick
Director Of Operations
Gadiel Rothe
Director Of Qa/Ra
OCON Therapeutics Email Formats
OCON Therapeutics uses 2 email formats. The most common is {first initial} (e.g., j@oconmed.com), used 54.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial} | j@oconmed.com | 54.5% |
{first name} | john@oconmed.com | 45.5% |
About OCON Therapeutics
OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. In addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications. OCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.
OCON Therapeutics revenue & valuation
| Annual revenue | $12,000,000 |
| Revenue per employee | $353,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $38,400,000 |
| Total funding | $14,500,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
OCON Therapeutics has 7 employees across 3 departments.
Departments
Number of employees
Funding Data
Explore OCON Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
OCON Therapeutics Tech Stack
Discover the technologies and tools that power OCON Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress plugins
JavaScript libraries
WordPress themes
Page builders
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Security
Programming languages
United Kingdom
United States
Sweden
South Africa
Frequently asked questions
4.8
40,000 users
